🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Myotonic Dystrophy

Muscle Health Measurements Using Electrical Impedance Myography NCT07502989n/a1 site📍 Boston Beth Israel Deaconess Medical Center · Tests: Electrical Impedance Myography Biomarker Development for Muscular Dystrophies NCT05019625n/a5 sites📍 Boston📍 Boston📍 Boston Massachusetts General Hospital An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) NCT07220603Phase 23 sites📍 Calgary📍 Ottawa📍 Saguenay PepGen Inc · Tests: PGN-EDODM1 Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy NCT06075693n/a1 site📍 Boston Massachusetts General Hospital Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy NCT07630389n/a1 site📍 Rochester University of Rochester Phenotype - Genotype Correlation in a Sample of Egyptian Patients With Congenital Myopathies and Congenital Muscular Dystrophies NCT07138963n/a1 site📍 Cairo Ain Shams University · Tests: Genetic Testing and Muscle Biopsy Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy NCT07362875n/a1 site📍 Winston-Salem Wake Forest University Health Sciences Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry NCT00082108n/a1 site📍 Rochester University of Rochester Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension NCT06747884n/a4 sites📍 Little Rock📍 Kansas City📍 Richmond Virginia Commonwealth University The United Kingdom National Registry for Myotonic Dystrophy NCT04003363n/a1 site📍 Newcastle upon Tyne Newcastle University · Tests: Patient Registry DMCRN-02-001: Assessing Pediatric Endpoints in DM1 NCT05224778n/a5 sites📍 Los Angeles📍 Fairway📍 Rochester Virginia Commonwealth University Molecular and Genetic Studies of Congenital Myopathies NCT00272883n/a1 site📍 Boston Boston Children's Hospital The Spanish National Registry for Myotonic Dystrophy Type 1 NCT07385443n/a8 sites📍 Multiple Locations📍 Multiple Locations📍 Multiple Locations Fundació Institut Germans Trias i Pujol · Tests: Patient Registry Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy NCT05004129Phase 2, Phase 314 sites📍 Little Rock📍 Los Angeles📍 Palo Alto AMO Pharma Limited · Tests: Tideglusib Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) NCT03981575n/a17 sites📍 La Jolla📍 Los Angeles📍 Denver Virginia Commonwealth University A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 NCT06844214Phase 1, Phase 210 sites📍 Gainesville📍 Tampa📍 New York Sanofi · Tests: SAR446268 Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension NCT07700225n/a1 site📍 Richmond Virginia Commonwealth University Long-Term Development of Muscular Dystrophy Outcome Assessments NCT05989620n/a1 site📍 Richmond Virginia Commonwealth University Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 NCT07486934Phase 343 sites📍 La Jolla📍 Los Angeles📍 Palo Alto Dyne Therapeutics · Tests: zeleciment basivarsen (DYNE-101), Placebo Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) NCT07608432Phase 31 site📍 Hillsborough Dyne Therapeutics · Tests: Zeleciment Rostudirsen (DYNE-251), Placebo Study of ATX-01 in Participants With DM1 NCT06300307Phase 1, Phase 212 sites📍 Los Angeles📍 Gainesville📍 Iowa City ARTHEx Biotech S.L. · Tests: ATX-01, Placebo VirtualPark_Pediatric NCT07580365NA4 sites📍 Bosisio Parini📍 Pisa📍 Pavia Istituto di Sistemi e Tecnologie Industriali Intelligenti p… · Tests: Dual-task cycling, Standard therapy Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology NCT07136844NA1 site📍 Liège Centre Hospitalier Universitaire de Liege · Tests: Syde, Dynamometric measurements of muscle strength, The 6-minute walk test (6MWT), The 10-meter test (10MWT), The 4 sta… A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping NCT07587242Phase 318 sites📍 Westmead📍 Leuven📍 Liège Avidity Biosciences, Inc. · Tests: AOC 1044, Placebo Remote Assessments and Genetic Determinants of Myotonic Dystrophy NCT07505342n/a1 site📍 Rochester University of Rochester A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 NCT06667453Phase 212 sites📍 Calgary📍 Ottawa📍 Chicoutimi PepGen Inc · Tests: PGN-EDODM1, Placebo Pelvic Floor Muscle Training for Women with Myotonic Dystrophy NCT06316778NA1 site📍 Jonquière Université de Sherbrooke · Tests: Pelvic floor muscle training Myotonic Dystrophy Family Registry NCT02398786n/a1 site📍 Oakland Myotonic Dystrophy Foundation · Tests: Patient-entered data Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation NCT06813443n/a3 sites📍 Bologna📍 Roma📍 Florence IRCCS Azienda Ospedaliero-Universitaria di Bologna The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 NCT06523400Phase 37 sites📍 Leuven📍 Aarhus📍 München Lupin Ltd. · Tests: Mexiletine granules for prolonged-release oral suspension, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy